EVGN
$0.87
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally.
Recent News
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline
Despite a drop in revenue, Evogene Ltd (EVGN) focuses on AI-driven innovations and strategic partnerships to enhance future growth prospects.
Evogene Ltd. Q4 2025 Earnings Call Summary
Moby summary of Evogene Ltd.'s Q4 2025 earnings call
Evogene: Q4 Earnings Snapshot
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $5.3 million in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had a loss of 61 cents. The agricultural company posted revenue of $314,000 in the period.
Evogene: Q3 Earnings Snapshot
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported profit of $3.9 million in its third quarter. The Rehovot, Israel-based company said it had profit of 44 cents per share. Losses, adjusted to account for discontinued operations, came to 31 cents per share.
Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed
ICL Group Ltd (NYSE:ICL) is among the 13 Best Magnesium Stocks to Invest in Now. Evogene Ltd. announced the successful sale of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd (NYSE:ICL). The acquisition, which was first revealed on April 21, 2025, comprises Lavie Bio’s patented Biology Driven Design technology platform, microbial bank, pipeline […]